Catalent to buy Juniper Pharmaceuticals in $133m deal

This article was originally published here

US-based Catalent has agreed to acquire Juniper Pharmaceuticals in a deal valued at around $133m.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply